Literature DB >> 17476554

Prostate cancer detection: magnetic resonance (MR) spectroscopic imaging.

Joan C Vilanova1, Joaquim Barceló.   

Abstract

Magnetic resonance spectroscopic imaging (MRSI) represents a noninvasive technique to extend the diagnostic evaluation of prostatic cancer, beyond the morphologic information provided by MR imaging throughout the detection of cellular metabolites (choline and citrate). MRSI combined with the anatomical information provided by MRI can improve the assessment cancer location and extent within the prostate, extracapsular spread and cancer aggressiveness; both before and after treatment. We review the performance of MRI with MRSI and the role in the detection, localization, staging and management of the patient pre- and posttherapy for prostate cancer.

Entities:  

Mesh：

Year:  2007        PMID： 17476554     DOI： 10.1007/s00261-007-9191-7

Source DB:  PubMed          Journal:  Abdom Imaging        ISSN： 0942-8925


  6 in total

1.  A magnetic resonance spectroscopy driven initialization scheme for active shape model based prostate segmentation.

Authors:  Robert Toth; Pallavi Tiwari; Mark Rosen; Galen Reed; John Kurhanewicz; Arjun Kalyanpur; Sona Pungavkar; Anant Madabhushi
Journal:  Med Image Anal       Date:  2010-10-28       Impact factor: 8.545

Review 2.  MRS and MRSI guidance in molecular medicine: targeting and monitoring of choline and glucose metabolism in cancer.

Authors:  Kristine Glunde; Lu Jiang; Siver A Moestue; Ingrid S Gribbestad
Journal:  NMR Biomed       Date:  2011-07       Impact factor: 4.044

3.  Modalities for imaging of prostate cancer.

Authors:  A H Hou; D Swanson; A B Barqawi
Journal:  Adv Urol       Date:  2010-03-17

Review 4.  Multiparametric magnetic resonance imaging in prostate cancer: present and future.

Authors:  John Kurhanewicz; Daniel Vigneron; Peter Carroll; Fergus Coakley
Journal:  Curr Opin Urol       Date:  2008-01       Impact factor: 2.309

5.  Hyperpolarized 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading.

Authors:  Mark J Albers; Robert Bok; Albert P Chen; Charles H Cunningham; Matt L Zierhut; Vickie Yi Zhang; Susan J Kohler; James Tropp; Ralph E Hurd; Yi-Fen Yen; Sarah J Nelson; Daniel B Vigneron; John Kurhanewicz
Journal:  Cancer Res       Date:  2008-10-15       Impact factor: 12.701

6.  Evaluation of lactate and alanine as metabolic biomarkers of prostate cancer using 1H HR-MAS spectroscopy of biopsy tissues.

Authors:  May-Britt Tessem; Mark G Swanson; Kayvan R Keshari; Mark J Albers; David Joun; Z Laura Tabatabai; Jeffry P Simko; Katsuto Shinohara; Sarah J Nelson; Daniel B Vigneron; Ingrid S Gribbestad; John Kurhanewicz
Journal:  Magn Reson Med       Date:  2008-09       Impact factor: 4.668
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.